SEC Form 4 · accession 0001214659-17-003554
Anthera Pharmaceuticals Inc · ANTH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
May Liu
Officer — Principal Accounting Officer
Period of report
May 20, 2017
Accepted (ET)
May 22, 2017 · 8:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001316175
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $1.63 | May 20, 2017 | A | 53,125 | A | — | May 20, 2027 | Common Stock | 53,125 | 53,125 | D |
Explanation of responses
- F1This stock option vests monthly in 36 equal installments. The vesting commencement date is May 20, 2019. Vesting of 25% if this option shall be accelerated on interim data of 75% patients enrolled in the Company's RESULT Phase 3 clinical trial, whichever is earlier. Following an acceleration of vesting of the options, the remaining unvested options shall vest in equal monthly installments through the remaining vesting period such that the entire award becomes fully vested 36 months from the vesting commencement date. This option will expire on May 20, 2027.